Posted
Update
Article written by
/2021/12/14/61b8b9accb57c_france-3.png)
Millions of French people suffer from migraines, so laboratories are entering this market. Like Pfizer which, after developing its vaccine against Covid, is embarking on treatments for headaches. Nabila Stoolon the set of 12/13, looked into this juicy market for laboratories.
According to a recent Inserm study, one adult out of 7 in the world suffers from migraine, which represents 1 billion people. In France, women are particularly affected: 20% against 10% of men, but also 5% of children. “The American Giant [Pfizer] therefore saw migraine treatments as a future financial windfall… […] Cost of this investment 11.6 billion dollars all the same!explains journalist Nabila Tabouri, Wednesday, May 11 on the set of 12/13.
With this sum, Pfizer bought another American laboratory, Biohaven Pharmaceuticals, a company specializing in neurology and neuropsychiatry, which has developed a substance considered innovative against migraines, Rime Gepant. “In reality, the effectiveness of this drug is modest. In a study published in 2020, Rime Gepant eliminated the migraine attack of 2 out of 10 patients in 2 hours. For specialists, this is not much!”presents the journalist.